Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?

Severe Acute Respiratory Distress Syndrome caused by a novel human coronavirus SARS-CoV-2 named COVID-19 and declared as a pandemic. This paper reviews the possibility of repurposing angiotensin type 1 receptor (AT1R) antagonists and vitamin D to treat COVID-19. ACE2 protein found on the cell membranes is the target of SARS-CoV-2 for entering into the host cells. Viral spike protein-binding with ACE2 down-regulates it. As ACE2 is known to protect the lung from injuries, SARS-CoV-2-induced ACE2 deficiency may expose patients to lung damage. AT1R antagonists and vitamin D increase the expression of ACE2 independently. Besides, vitamin D suppresses the compensatory increase in renin levels following the inhibition of the renin-angiotensin system by AT1R antagonists. Therefore, a combination of AT1R antagonists and vitamin D may offer protection against COVID-19 induced lung injury

Year of Publication: 2020
Contained in: The American journal of the medical sciences Vol. 360, No. 4 (2020), p. 338-341
All journal articles: Search for all articles in this journal
Language: English
Contributors: Rafiullah, Mohamed | Author
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 1406-16-2
COVID-19
Coronavirus
EC 3.4.15.1
EC 3.4.17.-
Journal Article
Review
SARS-CoV-2
SARS
angiotensin converting enzyme 2
Additional Keywords: Angiotensin II Type 1 Receptor Blockers
Animals
Betacoronavirus
Coronavirus Infections
Host-Pathogen Interactions
Humans
Pandemics
Peptidyl-Dipeptidase A
Pneumonia, Viral
Renin-Angiotensin System
Severe Acute Respiratory Syndrome
Virus Internalization
Vitamin D
Vitamins
ISSN: 1538-2990
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 09.10.2020
Date Revised 09.10.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32736832
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.amjms.2020.07.018
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04200nma a2200877 c 4500
001 NLM314049940
003 DE-601
005 20201010213355.0
007 cr uuu---uuuuu
008 200801s2020 000 0 eng d
024 7 |a 10.1016/j.amjms.2020.07.018  |2 doi 
028 5 2 |a pubmed20n1426.xml 
035 |a S0002-9629(20)30312-8 
035 |a (DE-599)NLM32736832 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Rafiullah, Mohamed 
245 1 0 |a Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 09.10.2020 
500 |a Date Revised 09.10.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved. 
520 |a Severe Acute Respiratory Distress Syndrome caused by a novel human coronavirus SARS-CoV-2 named COVID-19 and declared as a pandemic. This paper reviews the possibility of repurposing angiotensin type 1 receptor (AT1R) antagonists and vitamin D to treat COVID-19. ACE2 protein found on the cell membranes is the target of SARS-CoV-2 for entering into the host cells. Viral spike protein-binding with ACE2 down-regulates it. As ACE2 is known to protect the lung from injuries, SARS-CoV-2-induced ACE2 deficiency may expose patients to lung damage. AT1R antagonists and vitamin D increase the expression of ACE2 independently. Besides, vitamin D suppresses the compensatory increase in renin levels following the inhibition of the renin-angiotensin system by AT1R antagonists. Therefore, a combination of AT1R antagonists and vitamin D may offer protection against COVID-19 induced lung injury 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Angiotensin II Type 1 Receptor Blockers  |6 D047228  |a pharmacology  |6 Q000494  |a *therapeutic use  |6 Q000627 
653 2 |a Animals  |6 D000818 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a blood  |6 Q000097  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
653 2 |a Host-Pathogen Interactions  |6 D054884 
653 2 |a Humans  |6 D006801 
653 2 |a Pandemics  |6 D058873 
653 2 |a Peptidyl-Dipeptidase A  |6 D007703  |a blood  |6 Q000097 
653 2 |a Pneumonia, Viral  |6 D011024  |a blood  |6 Q000097  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
653 2 |a Renin-Angiotensin System  |6 D012084  |a drug effects  |6 Q000187 
653 2 |a Severe Acute Respiratory Syndrome  |6 D045169  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Virus Internalization  |6 D053586 
653 2 |a Vitamin D  |6 D014807  |a pharmacology  |6 Q000494  |a *therapeutic use  |6 Q000627 
653 2 |a Vitamins  |6 D014815  |a pharmacology  |6 Q000494  |a *therapeutic use  |6 Q000627 
655 7 |a COVID-19  |2 gnd 
655 7 |a Coronavirus  |2 gnd 
655 7 |a SARS  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a Angiotensin II Type 1 Receptor Blockers  |2 gnd 
655 7 |a Vitamins  |2 gnd 
655 7 |a Vitamin D  |2 gnd 
655 7 |a 1406-16-2  |2 gnd 
655 7 |a Peptidyl-Dipeptidase A  |2 gnd 
655 7 |a EC 3.4.15.1  |2 gnd 
655 7 |a angiotensin converting enzyme 2  |2 gnd 
655 7 |a EC 3.4.17.-  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Coronavirus 
689 1 2 |a SARS 
689 1 3 |a SARS-CoV-2 
689 1 |5 DE-601 
689 2 0 |a Angiotensin II Type 1 Receptor Blockers 
689 2 1 |a Vitamins 
689 2 2 |a Vitamin D 
689 2 3 |A r  |a 1406-16-2 
689 2 4 |a Peptidyl-Dipeptidase A 
689 2 5 |A r  |a EC 3.4.15.1 
689 2 6 |a angiotensin converting enzyme 2 
689 2 7 |A r  |a EC 3.4.17.- 
689 2 |5 DE-601 
773 0 8 |i in  |t The American journal of the medical sciences  |g Vol. 360, No. 4 (2020), p. 338-341  |q 360:4<338-341  |w (DE-601)NLM000046027  |x 1538-2990 
856 4 1 |u http://dx.doi.org/10.1016/j.amjms.2020.07.018  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 360  |j 2020  |e 4  |b 31  |c 10  |h 338-341